Mostrar el registro sencillo del ítem

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

dc.rights.licenseopenen_US
dc.contributor.authorCOLEON, Severin
dc.contributor.authorWIEDEMANN, Aurelie
dc.contributor.authorSURENAUD, Mathieu
dc.contributor.authorLACABARATZ, Christine
dc.contributor.authorHUE, Sophie
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPRAGUE, Melanie
dc.contributor.authorCERVANTES-GONZALEZ, Minerva
dc.contributor.authorWANG, Zhiqing
dc.contributor.authorELLIS, Jerome
dc.contributor.authorSANSONI, Amandine
dc.contributor.authorPIERINI, Camille
dc.contributor.authorBARDIN, Quentin
dc.contributor.authorFABREGUE, Manon
dc.contributor.authorSHARKAOUI, Sarah
dc.contributor.authorHOEST, Philippe
dc.contributor.authorDUPATY, Lea
dc.contributor.authorPICARD, Florence
dc.contributor.authorHAJJ, Marwa El
dc.contributor.authorCENTLIVRE, Mireille
dc.contributor.authorGHOSN, Jade
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorCARDINAUD, Sylvain
dc.contributor.authorMALISSEN, Bernard
dc.contributor.authorZURAWSKI, Gerard
dc.contributor.authorZARUBICA, Ana
dc.contributor.authorZURAWSKI, Sandra M.
dc.contributor.authorGODOT, Veronique
dc.contributor.authorLEVY, Yves
dc.date.accessioned2023-03-13T10:05:02Z
dc.date.available2023-03-13T10:05:02Z
dc.date.issued2022-06
dc.identifier.issn2352-3964en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172268
dc.description.abstractEnBackground : There is an urgent need of a new generation of vaccine that are able to enhance protection against SARS-CoV-2 and related variants of concern (VOC) and emerging coronaviruses. Methods : We identified conserved T- and B-cell epitopes from Spike (S) and Nucleocapsid (N) highly homologous to 38 sarbecoviruses, including SARS-CoV-2 VOCs, to design a protein subunit vaccine targeting antigens to Dendritic Cells (DC) via CD40 surface receptor (CD40.CoV2). Findings : CD40.CoV2 immunization elicited high levels of cross-neutralizing antibodies against SARS-CoV-2, VOCs, and SARS-CoV-1 in K18-hACE2 transgenic mice, associated with viral control and survival after SARS-CoV-2 challenge. A direct comparison of CD40.CoV2 with the mRNA BNT162b2 vaccine showed that the two vaccines were equally immunogenic in mice. We demonstrated the potency of CD40.CoV2 to recall in vitro human multi-epitope, functional, and cytotoxic SARS-CoV-2 S- and N-specific T-cell responses that are unaffected by VOC mutations and cross-reactive with SARS-CoV-1 and, to a lesser extent, MERS epitopes. Interpretatio : We report the immunogenicity and antiviral efficacy of the CD40.CoV2 vaccine in a preclinical model providing a framework for a pan-sarbecovirus vaccine. Fundings : This work was supported by INSERM and the Investissements d'Avenir program, Vaccine Research Institute (VRI), managed by the ANR and the CARE project funded from the Innovative Medicines Initiative 2 Joint Undertaking (JU).
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enCOVID-19
dc.subject.enPre-clinical model
dc.subject.enSarbecoviruses
dc.subject.enSARS-CoV-2
dc.subject.enVaccine
dc.title.enDesign, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ebiom.2022.104062en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35594660en_US
bordeaux.journalEBioMedicineen_US
bordeaux.volume80en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EBioMedicine&rft.date=2022-06&rft.volume=80&rft.eissn=2352-3964&rft.issn=2352-3964&rft.au=COLEON,%20Severin&WIEDEMANN,%20Aurelie&SURENAUD,%20Mathieu&LACABARATZ,%20Christine&HUE,%20Sophie&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/Abrir
Thumbnail
Nombre:
BPH_EBM_2022_Coleon.pdf
Tamaño:
3.759Mb
Formato:
PDF
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem